Effect of HER2/neu expression on survival in non-small-cell lung cancer

V. Korrapati, M. Gaffney, L. G. Larsson, L. Di Nunno, M. Riggs, R. S. Beissner, J. J. Rinehart, Frank Edmund Mott

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Major prognostic factors for early-stage non-small-cell lung cancer (NSCLC) are tumor size and nodal status. It has been suggested that HER2/neu overexpression may be related to poor prognosis in NSCLC. We evaluated the significance of HER2/neu overexpression on survival in patients with NSCLC. Data were collected on 239 patients treated surgically for stage I/II NSCLC between 1987 and 1996. None of the patients received adjuvant chemotherapy or radiation. Formalin-fixed, paraffin-embedded tumor tissue samples were stained with p185/HER2 receptor antibody. Results were reported as positive (2+, 3+) or negative (0, 1+) (Group A). A separate analysis considered only 3+ as positive (Group B). HER2/neu overexpression was seen in 18% in Group A (43 of 239) and 6% in Group B (15 of 239). HER2/neu overexpression was highest in bronchoalveolar cell carcinoma and adenocarcinoma. More stage I tumors were positive than stage II in both groups, but this was significant only in Group A (21% vs. 7%, P = 0.02). No difference was seen with age, gender, or grade for either group. In Group A, the relapse rate was 55% for HER2/neu-overexpressing tumors and 31% for HER2/neu-negative tumors (P = 0.003). Median time to relapse in patients with HER2/neu-positive tumors was 2.9 years; it was not reached in patients with HER2/neu-negative tumors. Median survival of patients with HER2/neu-positive tumors was 3.6 years compared to 5 years in patients with HER2/neu-negative tumors (P = 0.66). In Group B, the relapse rate was 60% for HER2/neu-overexpressing tumors and 33% for negative tumors (P = 0.036). Median time to relapse was 3.4 years in HER2/neu positive and had not been reached in negative tumors. There was no difference in 5-year survival rates for both groups (47% for HER2/neu positive and 50% for negative, P = 0.66.

Original languageEnglish (US)
Pages (from-to)216-219
Number of pages4
JournalClinical Lung Cancer
Volume2
Issue number3
StatePublished - Feb 1 2001

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Neoplasms
Recurrence
Adjuvant Chemotherapy
Paraffin
Formaldehyde
Adenocarcinoma
Survival Rate
Radiation
Carcinoma
Antibodies

Keywords

  • Adenocarcinoma
  • Bronchoalveolar cell carcinoma
  • HER2/neu expression
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Korrapati, V., Gaffney, M., Larsson, L. G., Di Nunno, L., Riggs, M., Beissner, R. S., ... Mott, F. E. (2001). Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clinical Lung Cancer, 2(3), 216-219.

Effect of HER2/neu expression on survival in non-small-cell lung cancer. / Korrapati, V.; Gaffney, M.; Larsson, L. G.; Di Nunno, L.; Riggs, M.; Beissner, R. S.; Rinehart, J. J.; Mott, Frank Edmund.

In: Clinical Lung Cancer, Vol. 2, No. 3, 01.02.2001, p. 216-219.

Research output: Contribution to journalArticle

Korrapati, V, Gaffney, M, Larsson, LG, Di Nunno, L, Riggs, M, Beissner, RS, Rinehart, JJ & Mott, FE 2001, 'Effect of HER2/neu expression on survival in non-small-cell lung cancer', Clinical Lung Cancer, vol. 2, no. 3, pp. 216-219.
Korrapati V, Gaffney M, Larsson LG, Di Nunno L, Riggs M, Beissner RS et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clinical Lung Cancer. 2001 Feb 1;2(3):216-219.
Korrapati, V. ; Gaffney, M. ; Larsson, L. G. ; Di Nunno, L. ; Riggs, M. ; Beissner, R. S. ; Rinehart, J. J. ; Mott, Frank Edmund. / Effect of HER2/neu expression on survival in non-small-cell lung cancer. In: Clinical Lung Cancer. 2001 ; Vol. 2, No. 3. pp. 216-219.
@article{c9eb5e829947464383e75188878aad7c,
title = "Effect of HER2/neu expression on survival in non-small-cell lung cancer",
abstract = "Major prognostic factors for early-stage non-small-cell lung cancer (NSCLC) are tumor size and nodal status. It has been suggested that HER2/neu overexpression may be related to poor prognosis in NSCLC. We evaluated the significance of HER2/neu overexpression on survival in patients with NSCLC. Data were collected on 239 patients treated surgically for stage I/II NSCLC between 1987 and 1996. None of the patients received adjuvant chemotherapy or radiation. Formalin-fixed, paraffin-embedded tumor tissue samples were stained with p185/HER2 receptor antibody. Results were reported as positive (2+, 3+) or negative (0, 1+) (Group A). A separate analysis considered only 3+ as positive (Group B). HER2/neu overexpression was seen in 18{\%} in Group A (43 of 239) and 6{\%} in Group B (15 of 239). HER2/neu overexpression was highest in bronchoalveolar cell carcinoma and adenocarcinoma. More stage I tumors were positive than stage II in both groups, but this was significant only in Group A (21{\%} vs. 7{\%}, P = 0.02). No difference was seen with age, gender, or grade for either group. In Group A, the relapse rate was 55{\%} for HER2/neu-overexpressing tumors and 31{\%} for HER2/neu-negative tumors (P = 0.003). Median time to relapse in patients with HER2/neu-positive tumors was 2.9 years; it was not reached in patients with HER2/neu-negative tumors. Median survival of patients with HER2/neu-positive tumors was 3.6 years compared to 5 years in patients with HER2/neu-negative tumors (P = 0.66). In Group B, the relapse rate was 60{\%} for HER2/neu-overexpressing tumors and 33{\%} for negative tumors (P = 0.036). Median time to relapse was 3.4 years in HER2/neu positive and had not been reached in negative tumors. There was no difference in 5-year survival rates for both groups (47{\%} for HER2/neu positive and 50{\%} for negative, P = 0.66.",
keywords = "Adenocarcinoma, Bronchoalveolar cell carcinoma, HER2/neu expression, Prognosis",
author = "V. Korrapati and M. Gaffney and Larsson, {L. G.} and {Di Nunno}, L. and M. Riggs and Beissner, {R. S.} and Rinehart, {J. J.} and Mott, {Frank Edmund}",
year = "2001",
month = "2",
day = "1",
language = "English (US)",
volume = "2",
pages = "216--219",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Effect of HER2/neu expression on survival in non-small-cell lung cancer

AU - Korrapati, V.

AU - Gaffney, M.

AU - Larsson, L. G.

AU - Di Nunno, L.

AU - Riggs, M.

AU - Beissner, R. S.

AU - Rinehart, J. J.

AU - Mott, Frank Edmund

PY - 2001/2/1

Y1 - 2001/2/1

N2 - Major prognostic factors for early-stage non-small-cell lung cancer (NSCLC) are tumor size and nodal status. It has been suggested that HER2/neu overexpression may be related to poor prognosis in NSCLC. We evaluated the significance of HER2/neu overexpression on survival in patients with NSCLC. Data were collected on 239 patients treated surgically for stage I/II NSCLC between 1987 and 1996. None of the patients received adjuvant chemotherapy or radiation. Formalin-fixed, paraffin-embedded tumor tissue samples were stained with p185/HER2 receptor antibody. Results were reported as positive (2+, 3+) or negative (0, 1+) (Group A). A separate analysis considered only 3+ as positive (Group B). HER2/neu overexpression was seen in 18% in Group A (43 of 239) and 6% in Group B (15 of 239). HER2/neu overexpression was highest in bronchoalveolar cell carcinoma and adenocarcinoma. More stage I tumors were positive than stage II in both groups, but this was significant only in Group A (21% vs. 7%, P = 0.02). No difference was seen with age, gender, or grade for either group. In Group A, the relapse rate was 55% for HER2/neu-overexpressing tumors and 31% for HER2/neu-negative tumors (P = 0.003). Median time to relapse in patients with HER2/neu-positive tumors was 2.9 years; it was not reached in patients with HER2/neu-negative tumors. Median survival of patients with HER2/neu-positive tumors was 3.6 years compared to 5 years in patients with HER2/neu-negative tumors (P = 0.66). In Group B, the relapse rate was 60% for HER2/neu-overexpressing tumors and 33% for negative tumors (P = 0.036). Median time to relapse was 3.4 years in HER2/neu positive and had not been reached in negative tumors. There was no difference in 5-year survival rates for both groups (47% for HER2/neu positive and 50% for negative, P = 0.66.

AB - Major prognostic factors for early-stage non-small-cell lung cancer (NSCLC) are tumor size and nodal status. It has been suggested that HER2/neu overexpression may be related to poor prognosis in NSCLC. We evaluated the significance of HER2/neu overexpression on survival in patients with NSCLC. Data were collected on 239 patients treated surgically for stage I/II NSCLC between 1987 and 1996. None of the patients received adjuvant chemotherapy or radiation. Formalin-fixed, paraffin-embedded tumor tissue samples were stained with p185/HER2 receptor antibody. Results were reported as positive (2+, 3+) or negative (0, 1+) (Group A). A separate analysis considered only 3+ as positive (Group B). HER2/neu overexpression was seen in 18% in Group A (43 of 239) and 6% in Group B (15 of 239). HER2/neu overexpression was highest in bronchoalveolar cell carcinoma and adenocarcinoma. More stage I tumors were positive than stage II in both groups, but this was significant only in Group A (21% vs. 7%, P = 0.02). No difference was seen with age, gender, or grade for either group. In Group A, the relapse rate was 55% for HER2/neu-overexpressing tumors and 31% for HER2/neu-negative tumors (P = 0.003). Median time to relapse in patients with HER2/neu-positive tumors was 2.9 years; it was not reached in patients with HER2/neu-negative tumors. Median survival of patients with HER2/neu-positive tumors was 3.6 years compared to 5 years in patients with HER2/neu-negative tumors (P = 0.66). In Group B, the relapse rate was 60% for HER2/neu-overexpressing tumors and 33% for negative tumors (P = 0.036). Median time to relapse was 3.4 years in HER2/neu positive and had not been reached in negative tumors. There was no difference in 5-year survival rates for both groups (47% for HER2/neu positive and 50% for negative, P = 0.66.

KW - Adenocarcinoma

KW - Bronchoalveolar cell carcinoma

KW - HER2/neu expression

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0034460979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034460979&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 216

EP - 219

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -